XML 16 R6.htm IDEA: XBRL DOCUMENT v3.3.1.900
Statements of Cash Flows - USD ($)
 6 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Cash flows from operating activities    
Net loss $ (5,608,568) $ (3,725,772)
Stock-based compensation expense 250,887 477,660
Depreciation, amortization and accretion 242,427 49,164
Amoritzation of debt issuance costs 147,805 0
Derivative expense 78,038 0
Amortization of prepaid research and development - related party (Note 11) 60,991 60,992
Deferred taxes 0 (23,910)
Adjustments to reconcile net loss to net cash used in operating activities:    
(Increase) in accounts receivable (131,408) (6,906)
(Increase) in inventory (613,673) (10,453)
(Increase) decrease in prepaid expenses, other (370,656) 485,889
(Increase) in prepaid research and development - related party (Note 11) 0 (150,000)
(Decrease) in accounts payable and accrued liabilities (126,781) (298,677)
Increase (decrease) in related party payable 38,451 (561,059)
Increase in accrued compensation 296,081 94,247
Increase in interest payable 161,988 74,936
Increase in deferred rent 10,245 0
(Decrease) in deferred revenue (42,857) (42,858)
Net cash used in operating activities (5,607,030) (3,576,747)
Cash flows used in investing activities    
Deposits 1,998 (1,998)
Purchases of fixed assets (125,161) 0
Purchase of Primsol business (540,000) 0
Net cash used in investing activities (663,163) (1,998)
Cash flows from financing activities    
Proceeds from convertible promissory notes, net (Note 8) 5,175,000 0
Debt issuance costs (Note 8) (298,322)  
Ampio stock subscription payment 5,000,000 0
Contribution from Ampio 0 1,100,000
Net cash provided by financing activities 9,876,678 1,100,000
Net change in cash and cash equivalents 3,606,485 (2,478,745)
Cash and cash equivalents at beginning of period 7,353,061 2,639,650
Cash and cash equivalents at end of period 10,959,546 160,905
Non-cash transactions:    
Warrant derivative liability related to the issuance of the convertible promissory notes (Note 8) 102,931 0
Primsol business purchase included in primsol payable, $1,250,000 less future accretion of $173,000 1,077,000 0
Fixed asset purchases included in accounts payable $ 7,708 $ 0